1. Home
  2. PHAT vs FCBC Comparison

PHAT vs FCBC Comparison

Compare PHAT & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • FCBC
  • Stock Information
  • Founded
  • PHAT 2018
  • FCBC 1874
  • Country
  • PHAT United States
  • FCBC United States
  • Employees
  • PHAT N/A
  • FCBC N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • FCBC Major Banks
  • Sector
  • PHAT Health Care
  • FCBC Finance
  • Exchange
  • PHAT Nasdaq
  • FCBC Nasdaq
  • Market Cap
  • PHAT 727.5M
  • FCBC 681.6M
  • IPO Year
  • PHAT 2019
  • FCBC 1992
  • Fundamental
  • Price
  • PHAT $9.45
  • FCBC $40.41
  • Analyst Decision
  • PHAT Strong Buy
  • FCBC
  • Analyst Count
  • PHAT 5
  • FCBC 0
  • Target Price
  • PHAT $16.40
  • FCBC N/A
  • AVG Volume (30 Days)
  • PHAT 1.7M
  • FCBC 78.3K
  • Earning Date
  • PHAT 08-07-2025
  • FCBC 07-22-2025
  • Dividend Yield
  • PHAT N/A
  • FCBC 3.02%
  • EPS Growth
  • PHAT N/A
  • FCBC 3.83
  • EPS
  • PHAT N/A
  • FCBC 2.74
  • Revenue
  • PHAT $81,859,000.00
  • FCBC $162,590,000.00
  • Revenue This Year
  • PHAT $195.03
  • FCBC $2.34
  • Revenue Next Year
  • PHAT $106.77
  • FCBC $1.10
  • P/E Ratio
  • PHAT N/A
  • FCBC $14.70
  • Revenue Growth
  • PHAT 3055.70
  • FCBC 1.13
  • 52 Week Low
  • PHAT $2.21
  • FCBC $33.88
  • 52 Week High
  • PHAT $19.71
  • FCBC $49.02
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 60.80
  • FCBC 57.07
  • Support Level
  • PHAT $8.19
  • FCBC $38.81
  • Resistance Level
  • PHAT $9.76
  • FCBC $41.67
  • Average True Range (ATR)
  • PHAT 0.66
  • FCBC 1.11
  • MACD
  • PHAT -0.21
  • FCBC 0.14
  • Stochastic Oscillator
  • PHAT 54.58
  • FCBC 62.39

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About FCBC First Community Bankshares Inc. (VA)

First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.

Share on Social Networks: